Literature DB >> 1520769

Epidemiology and clinical significance of nontuberculous mycobacteria in patients negative for human immunodeficiency virus in Switzerland.

M Debrunner1, M Salfinger, O Brändli, A von Graevenitz.   

Abstract

Over the last decades, the rate of isolation of tubercle bacilli has declined in the developed countries, while the incidence of infection with nontuberculous mycobacteria (NTM) has increased. In a retrospective study, we analyzed all cases of patients negative for human immunodeficiency virus (HIV) and from whom NTM were isolated in the Zurich area of Switzerland from 1983 to 1988. During the 6-year study period, 513 patients infected with NTM were identified, 34 of whom had clinically significant disease. The presentation of mycobacteriosis was found to be lung disease in 23 cases, soft-tissue disease in 10 cases, and disseminated disease in one case. The highest attack rate of pulmonary mycobacteriosis was 0.49% and was found in the group of patients 41-50 years old. During the 6-year period, the incidence of tuberculosis declined from 16.2 to 13.2 per 100,000 population, while the incidence of mycobacteriosis increased from 0.4 to 0.9 per 100,000 population. Clinically nonsignificant NTM isolates were found more frequently in patients with chronic lung diseases (P less than .01) and especially in patients with a history of tuberculosis (P less than .001).

Entities:  

Mesh:

Year:  1992        PMID: 1520769     DOI: 10.1093/clinids/15.2.330

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  PCR-enzyme-linked immunosorbent assay and partial rRNA gene sequencing: a rational approach to identifying mycobacteria.

Authors:  S Patel; M Yates; N A Saunders
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Prospective evaluation of the GenoType assay for routine identification of mycobacteria.

Authors:  A Sarkola; J Mäkinen; M Marjamäki; H J Marttila; M K Viljanen; H Soini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

3.  Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003.

Authors:  Theodore K Marras; Pamela Chedore; Alicia M Ying; Frances Jamieson
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

Review 4.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Nontuberculous mycobacterial infections among patients suspected of pulmonary tuberculosis.

Authors:  H Grubek-Jaworska; R Walkiewicz; A Safianowska; M Nowacka-Mazurek; R Krenke; T Przybyłowski; R Chazan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-14       Impact factor: 3.267

6.  The presence of atypical mycobacteria in the mouthwashes of normal subjects: role of tap water and oral hygiene.

Authors:  Siraj O Wali; M M Abdelaziz; A B Krayem; Y S Samman; A N Shukairi; S A Mirdad; A S Albanna; H J Alghamdi; A O Osoba
Journal:  Ann Thorac Med       Date:  2008-01       Impact factor: 2.219

Review 7.  The new diagnostic mycobacteriology laboratory.

Authors:  M Salfinger; G E Pfyffer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

8.  Invasive infection with Mycobacterium genavense in three children with the acquired immunodeficiency syndrome.

Authors:  D Nadal; R Caduff; R Kraft; M Salfinger; T Bodmer; P Kirschner; E C Böttger; U B Schaad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

9.  Genetic characterization of Mycobacterium avium isolates recovered from humans and animals in Australia.

Authors:  M M Feizabadi; I D Robertson; D V Cousins; D Dawson; W Chew; G L Gilbert; D J Hampson
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

Review 10.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.